Pharmacy Drugs
Recent Posts
- EPIX Pharmaceuticals Announces FDA Approval Of A Physician-Sponsored IND For Fourth 6-month Open Label Extension Of PRX-03140 For Alzheimer’s Disease
- Miriam Hospital Researcher Receives More Than $12 Million To Study Weight Control
- Novel HIV Drug To Be Studied In Cell Cultures And Patients
- ISCTM Meeting Discusses Clinical And Regulatory Aspects Of Using Adaptive Designs In Clinical Trials For Central Nervous System Drug Approvals
- Evaluation Of The Cost Effectiveness Of Implantable Blood Pressure Device
Random Posts
- Excess Body Weight Causes Over 124,000 New Cancers A Year In Europe
- Independent Pharmacists Raise Concerns Over Letters From CVS Caremark Indicating Members Must Pay Higher Copayments At Non-CVS Pharmacies
- Radiant Research, Inc. Prepares For Upcoming H1N1 Vaccine Trials
- BioClinica Advances Standards Support At DIA 2009
- New Software To Improve Clinical Trial Performance
- Diet High In Methionine Could Increase Risk Of Alzheimer's
- Drug Companies Defend Acetaminophen as FDA Considers Restrictions
- New Antipsychotics Lead to Weight Gain in Young Patients (CME/CE)
- Medication Plus Parent Training Improves Behavioral Problems In Children With PDD
- Sensitizing Leukemic Cells To Death-Inducing Compounds
Néovacs To Expand Clinical Testing Of Its TNF-alpha Kinoid Lead Product Candidate Following Positive Preliminary Findings From A Phase I/II Study
Posted by: admin in Pharmacy Drugs on June 25th, 2009
Neovacs, a biotechnology company developing proprietary immunotherapeutics for autoimmune and chronic diseases, announced that subject to regulatory consent, it plans to initiate a Phase II study of its TNF-alpha Kinoid later this year in rheumatoid arthritis patients who have failed treatment with at least one TNF-alpha inhibitor. The decision to proceed with the trial was based on an initial review of encouraging data from the company’s Phase I/II study in Crohn’s disease.
The proposed trial will initially test two dose levels of the TNF-Kinoid, with the option of expanding recruitment and extending follow-up in one dose group on the basis of serological and clinical responses. The multicentre, Europe-wide trial received significant public funding from OSEO, the French state innovation agency.
“We are highly encouraged by the safety data and preliminary indications of efficacy that are emerging from our Crohn’s disease study,” commented Neovacs CEO Guy-Charles Fanneau de La Horie. “With all the initial dose groups having received the Kinoid, we have not seen any significant adverse reactions; importantly, it is very clear that the Kinoid does not induce cell-mediated immunity. Furthermore, all the patients in the higher dose groups treated to date have mounted an antibody response and are in clinical remission. It makes sense to take a further step forward by testing the Kinoid in a Phase II rheumatoid arthritis trial. We are grateful for the public funding that is enabling us to expand our clinical efforts without delay”, added Mr de la Horie.
The ongoing Phase I/II dose-escalation study (taking place in South Africa and Switzerland) is recruiting between 12 and 18 patients with active Crohn’s Disease and is intended to evaluate the Kinoid’s safety and immunogenicity. In the context of active immunotherapy, safety parameters include (i) the absence of adverse reactions and (ii) serological measurements of the nature of the immune response, such as the kinetics of the antibody response and whether the cellular immune system (and specifically T cell memory) is stimulated. The trial is also tracking a clinical endpoint for disease status - the Crohn’s Disease Activity Index.
Source
Neovacs
No Comments »
No comments yet.
RSS feed for comments on this post. TrackBack URL
Leave a comment
You must be logged in to post a comment.